8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 25, 2026·SEC
Material company update
Feb 25, 2026·SEC
Alkermes plc(ALKS)Earnings, Financials & Key Ratios
ALKS•NASDAQ
$35.32
$5.89B mkt cap·24.7× P/E·Price updated May 6, 2026
AboutAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Show more
- Revenue$1.48B-5.2%
- EBITDA$281M-37.4%
- Net Income$242M-34.2%
- EPS (Diluted)1.43-34.1%
- Gross Margin86.69%+2.9%
- EBITDA Margin19.05%-33.9%
- Operating Margin17.21%-36.3%
- Net Margin16.37%-30.5%
- ROE14.72%-46.5%
- ROIC18.87%-29.2%
- Debt/Equity0.04-25.4%
- Interest Coverage24.74+19.8%
ALKS Key Insights
Alkermes plc (ALKS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Excellent 3Y average ROE of 24.6%
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 32.5% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading near 52-week high
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ALKS Price & Volume
Alkermes plc (ALKS) stock price & volume — 10-year historical chart
Loading chart...
ALKS Growth Metrics
Alkermes plc (ALKS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.91%
5 Years7.28%
3 Years9.9%
TTM3.21%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-56.7%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-56.94%
Return on Capital
10 Years2.38%
5 Years14.66%
3 Years22.44%
Last Year14.2%
ALKS Recent Earnings
Alkermes plc (ALKS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 5, 2026EPS
$0.40
Est $0.57
+29.8%
Revenue
$393M
Est $363M
+8.2%
Q1 2026
Feb 25, 2026EPS
$0.34
Est $0.43
-20.9%
Revenue
$385M
Est $379M
+1.5%
Q4 2025
Oct 28, 2025EPS
$0.49
Est $0.42
+16.7%
Revenue
$394M
Est $380M
+3.8%
Q3 2025
Jul 29, 2025EPS
$0.52
Est $0.41
+26.8%
Revenue
$391M
Est $355M
+10.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.40vs $0.57+29.8% | $393Mvs $363M+8.2% |
| Q1 2026 | Feb 25, 2026 | $0.34vs $0.43-20.9% | $385Mvs $379M+1.5% |
| Q4 2025 | Oct 28, 2025 | $0.49vs $0.42+16.7% | $394Mvs $380M+3.8% |
| Q3 2025 | Jul 29, 2025 | $0.52vs $0.41+26.8% | $391Mvs $355M+10.2% |
Based on last 12 quarters of dataView full earnings history →
ALKS Peer Comparison
Alkermes plc (ALKS) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 AXSM | 11.46B | 222.63 | -60.50 | 65.55% | -26.59% | -260.01% | 2.73 | |
 INTR | 2.54B | 7.84 | 18.70 | 27.12% | 12.37% | 1.31 | ||
 JAZZ | 14.34B | 228.57 | -39.14 | 4.88% | 0.66% | 0.71% | 1.26 | |
 TEVA | 42.31B | 36.34 | 30.28 | 4.31% | 9.02% | 20.69% | 2.20 | |
 BHC | 2.11B | 5.65 | 13.14 | 8.53% | -11.27% | 5.88% | 56.36 |
Compare ALKS vs Peers
Alkermes plc (ALKS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALKS Income Statement
Alkermes plc (ALKS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 903.37M | 1.09B | 1.17B | 1.04B | 1.17B | 1.11B | 1.66B | 1.56B | 1.48B | 1.56B |
| Revenue Growth % | 21.15% | 21.13% | 7.01% | -11.29% | 13% | -5.28% | 49.61% | -6.36% | -5.25% | 3.21% |
| Cost of Goods Sold | 154.75M | 176.42M | 180.38M | 178.32M | 197.32M | 218.07M | 253.04M | 245.33M | 196.46M | 147.26M |
| COGS % of Revenue | 17.13% | 16.12% | 15.41% | 17.17% | 16.81% | 19.61% | 15.21% | 15.75% | 13.31% | - |
| Gross Profit | 748.63M▲ 0% | 917.85M▲ 22.6% | 990.56M▲ 7.9% | 860.44M▼ 13.1% | 976.43M▲ 13.5% | 893.73M▼ 8.5% | 1.41B▲ 57.8% | 1.31B▼ 7.0% | 1.28B▼ 2.5% | 1.02B▲ 0% |
| Gross Margin % | 82.87% | 83.88% | 84.59% | 82.83% | 83.19% | 80.39% | 84.79% | 84.25% | 86.69% | 65.42% |
| Gross Profit Growth % | 22.01% | 22.61% | 7.92% | -13.14% | 13.48% | -8.47% | 57.81% | -6.95% | -2.5% | - |
| Operating Expenses | 896.53M | 1.02B | 1.17B | 972.87M | 878.68M | 899.82M | 996.25M | 891.66M | 1.03B | 1.15B |
| OpEx % of Revenue | 99.24% | 92.94% | 99.58% | 93.66% | 74.86% | 80.93% | 59.89% | 57.24% | 69.48% | - |
| Selling, General & Admin | 421.58M | 526.41M | 599.45M | 538.83M | 549.61M | 590.75M | 689.75M | 645.24M | 701.52M | 794.41M |
| SG&A % of Revenue | 46.67% | 48.11% | 51.19% | 51.87% | 46.83% | 53.13% | 41.47% | 41.42% | 47.53% | - |
| Research & Development | 412.89M | 425.41M | 512.83M | 394.59M | 290.92M | 272.7M | 270.81M | 245.33M | 323.96M | 355.49M |
| R&D % of Revenue | 45.71% | 38.88% | 43.8% | 37.99% | 24.79% | 24.53% | 16.28% | 15.75% | 21.95% | - |
| Other Operating Expenses | 62.06M | 65.17M | 53.76M | 39.45M | 38.15M | 36.36M | 35.69M | 1.1M | 0 | 0 |
| Operating Income | -147.9M▲ 0% | -99.13M▲ 33.0% | -175.48M▼ 77.0% | -112.43M▲ 35.9% | 97.75M▲ 186.9% | -6.09M▼ 106.2% | 414.12M▲ 6901.1% | 420.64M▲ 1.6% | 253.96M▼ 39.6% | 191.88M▲ 0% |
| Operating Margin % | -16.37% | -9.06% | -14.99% | -10.82% | 8.33% | -0.55% | 24.9% | 27% | 17.21% | 12.28% |
| Operating Income Growth % | 29.12% | 32.98% | -77.02% | 35.93% | 186.94% | -106.23% | 6901.15% | 1.57% | -39.63% | - |
| EBITDA | -49.38M | 4.53M | -95.07M | -30.57M | 176.4M | 71.77M | 489.05M | 449.17M | 281.12M | 211.63M |
| EBITDA Margin % | -5.47% | 0.41% | -8.12% | -2.94% | 15.03% | 6.46% | 29.4% | 28.84% | 19.05% | 13.55% |
| EBITDA Growth % | 56.84% | 109.18% | -2197.66% | 67.84% | 676.97% | -59.31% | 581.38% | -8.15% | -37.41% | -49.49% |
| D&A (Non-Cash Add-back) | 98.52M | 103.66M | 80.41M | 81.85M | 78.65M | 77.86M | 74.93M | 28.53M | 27.16M | 19.74M |
| EBIT | -131.27M | -111.53M | -183.46M | -87.88M | 98.95M | -18.09M | 444.55M | 466.33M | 303.73M | 278.24M |
| Net Interest Income | -7.36M | -6.2M | 375K | -1.7M | -8.81M | -5.41M | 7.82M | 19.87M | 33.03M | 22.89M |
| Interest Income | 4.65M | 9.24M | 13.98M | 6.96M | 2.41M | 7.63M | 30.85M | 42.45M | 45.3M | 43.7M |
| Interest Expense | 12.01M | 15.44M | 13.6M | 8.66M | 11.22M | 13.04M | 23.03M | 22.58M | 12.28M | -8.62M |
| Other Income/Expense | 4.63M | -27.84M | -21.58M | 15.89M | -10.02M | -25.04M | 7.4M | 23.11M | 37.49M | 12.15M |
| Pretax Income | -143.27M▲ 0% | -126.97M▲ 11.4% | -197.06M▼ 55.2% | -96.54M▲ 51.0% | 87.73M▲ 190.9% | -31.13M▼ 135.5% | 421.52M▲ 1454.1% | 443.75M▲ 5.3% | 291.45M▼ 34.3% | 204.03M▲ 0% |
| Pretax Margin % | -15.86% | -11.6% | -16.83% | -9.29% | 7.47% | -2.8% | 25.34% | 28.49% | 19.75% | 13.06% |
| Income Tax | 14.67M | 12.34M | -436K | 14.32M | 11.33M | 2.02M | -97.64M | 71.61M | 49.79M | 51.31M |
| Effective Tax Rate % | -10.24% | -9.72% | 0.22% | -14.84% | 12.91% | -6.5% | -23.16% | 16.14% | 17.08% | 25.15% |
| Net Income | -157.94M▲ 0% | -139.31M▲ 11.8% | -196.62M▼ 41.1% | -110.86M▲ 43.6% | -48.17M▲ 56.6% | -158.27M▼ 228.6% | 355.76M▲ 324.8% | 367.07M▲ 3.2% | 241.66M▼ 34.2% | 152.72M▲ 0% |
| Net Margin % | -17.48% | -12.73% | -16.79% | -10.67% | -4.1% | -14.24% | 21.39% | 23.57% | 16.37% | 9.78% |
| Net Income Growth % | 24.23% | 11.8% | -41.14% | 43.62% | 56.55% | -228.57% | 324.78% | 3.18% | -34.16% | -56.7% |
| Net Income (Continuing) | -157.94M | -139.31M | -196.62M | -110.86M | 76.4M | -33.15M | 519.16M | 372.14M | 241.66M | 152.72M |
| Discontinued Operations | 0 | 0 | 0 | 0 | -124.57M | -125.11M | -163.4M | -5.07M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.03▲ 0% | -0.90▲ 12.6% | -1.25▼ 38.9% | -0.70▲ 44.0% | -0.30▲ 57.1% | -0.97▼ 223.3% | 2.10▲ 316.5% | 2.17▲ 3.3% | 1.43▼ 34.1% | 0.92▲ 0% |
| EPS Growth % | 25.36% | 12.62% | -38.89% | 44% | 57.14% | -223.33% | 316.49% | 3.33% | -34.1% | -56.94% |
| EPS (Basic) | -1.03 | -0.90 | -1.25 | -0.70 | -0.30 | -0.97 | 2.14 | 2.22 | 1.47 | - |
| Diluted Shares Outstanding | 153.41M | 155.11M | 157.05M | 158.8M | 160.94M | 163.74M | 169.73M | 169.2M | 168.74M | 166.2M |
| Basic Shares Outstanding | 153.41M | 155.11M | 157.05M | 158.8M | 160.94M | 163.74M | 166.22M | 165.39M | 164.7M | 166.2M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ALKS Balance Sheet
Alkermes plc (ALKS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 966.06M | 983.25M | 961.97M | 1.11B | 1.06B | 1.13B | 1.49B | 1.42B | 1.93B | 1.28B |
| Cash & Short-Term Investments | 590.72M | 539.29M | 534.98M | 635.03M | 536.31M | 608.47M | 773.49M | 751.67M | 1.32B | 538.23M |
| Cash Only | 191.3M | 266.76M | 203.77M | 272.96M | 337.54M | 292.47M | 457.47M | 291.15M | 1.12B | 538.23M |
| Short-Term Investments | 242.21M | 272.53M | 331.21M | 362.07M | 198.77M | 315.99M | 316.02M | 460.52M | 199.65M | 0 |
| Accounts Receivable | 233.59M | 300.45M | 265.47M | 289.54M | 326.56M | 296.9M | 333.18M | 389.52M | 334.02M | 407.63M |
| Days Sales Outstanding | 94.38 | 100.22 | 82.75 | 101.74 | 101.55 | 97.47 | 73.11 | 91.28 | 82.61 | 84.79 |
| Inventory | 93.28M | 90.2M | 101.8M | 125.74M | 150.34M | 181.42M | 186.41M | 182.89M | 196.63M | 336.7M |
| Days Inventory Outstanding | 220.01 | 186.61 | 205.99 | 257.38 | 278.08 | 303.66 | 268.89 | 272.1 | 365.31 | 567.76 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 43.53M | 192.43M | 91.28M | 79.09M | 0 |
| Total Non-Current Assets | 831.17M | 841.75M | 843.43M | 838.76M | 962.32M | 833.67M | 650.72M | 640.21M | 601.09M | 2.74B |
| Property, Plant & Equipment | 284.74M | 309.99M | 374.55M | 481.72M | 456.68M | 320.46M | 318.4M | 311.81M | 298.93M | 220.59M |
| Fixed Asset Turnover | 3.17x | 3.53x | 3.13x | 2.16x | 2.57x | 3.47x | 5.22x | 5.00x | 4.94x | 5.36x |
| Goodwill | 92.87M | 92.87M | 92.87M | 92.87M | 92.87M | 83.03M | 83.03M | 83.03M | 0 | 596.03M |
| Intangible Assets | 256.17M | 191M | 150.64M | 111.19M | 74.04M | 37.68M | 1.99M | 890K | 83.84M | 1.78B |
| Long-Term Investments | 157.21M | 80.74M | 79.39M | 24.78M | 229.43M | 131.61M | 39.89M | 73.15M | 145K | 66.28M |
| Other Non-Current Assets | -58.38M | 81.34M | 49.42M | 41.97M | 27.45M | 146.32M | 11.52M | 16.5M | 49.1M | 88.67M |
| Total Assets | 1.8B▲ 0% | 1.83B▲ 1.5% | 1.81B▼ 1.1% | 1.95B▲ 8.0% | 2.02B▲ 3.8% | 1.96B▼ 3.0% | 2.14B▲ 8.8% | 2.06B▼ 3.8% | 2.53B▲ 23.1% | 4.26B▲ 0% |
| Asset Turnover | 0.50x | 0.60x | 0.65x | 0.53x | 0.58x | 0.57x | 0.78x | 0.76x | 0.58x | 0.55x |
| Asset Growth % | 4.1% | 1.55% | -1.07% | 7.99% | 3.83% | -2.99% | 8.77% | -3.78% | 23.09% | 137.78% |
| Total Current Liabilities | 291.12M | 339.77M | 391.11M | 438.26M | 471.29M | 497.74M | 520.22M | 465.2M | 543.44M | 599.5M |
| Accounts Payable | 55.53M | 39.77M | 54.26M | 46.03M | 55.72M | 32.84M | 65.65M | 45.63M | 107.95M | 0 |
| Days Payables Outstanding | 130.97 | 82.28 | 109.79 | 94.23 | 103.07 | 54.97 | 94.7 | 67.89 | 200.56 | 170.5 |
| Short-Term Debt | 3M | 2.84M | 2.84M | 2.84M | 3M | 3M | 3M | 0 | 6.75M | 34.08M |
| Deferred Revenue (Current) | 1.96M | 3.17M | 6.77M | 7.51M | 6.34M | 6.82M | 2.73M | 1.25M | 0 | 0 |
| Other Current Liabilities | 176.07M | 226.38M | 72.07M | 71.18M | 77.26M | 84.93M | 359.99M | 70.96M | 428.74M | 565.42M |
| Current Ratio | 3.32x | 2.89x | 2.46x | 2.53x | 2.25x | 2.27x | 2.86x | 3.04x | 3.55x | 3.55x |
| Quick Ratio | 3.00x | 2.63x | 2.20x | 2.25x | 1.93x | 1.91x | 2.50x | 2.65x | 3.19x | 3.19x |
| Cash Conversion Cycle | 183.42 | 204.55 | 178.95 | 264.89 | 276.56 | 346.15 | 247.3 | 295.48 | 247.36 | 482.04 |
| Total Non-Current Liabilities | 303.3M | 313.95M | 328.85M | 444.49M | 440.61M | 422.48M | 413.32M | 125.39M | 167.52M | 1.91B |
| Long-Term Debt | 278.44M | 276.46M | 274.3M | 272.12M | 292.8M | 290.27M | 287.73M | 0 | 0 | 1.48B |
| Capital Lease Obligations | 0 | 0 | 5.34M | 119.46M | 104.16M | 76.29M | 75.71M | 69.37M | 63.25M | 194.44M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | -4.78M | 0 | 43.26M | 225.18M |
| Other Non-Current Liabilities | 19.2M | 27.96M | 27.14M | 36.51M | 32.16M | 55.93M | 49.88M | 56.02M | 61.01M | 351.35M |
| Total Liabilities | 594.42M | 653.72M | 719.96M | 882.75M | 911.9M | 920.23M | 933.54M | 590.59M | 710.96M | 2.51B |
| Total Debt | 281.44M | 279.31M | 290.95M | 410.16M | 416.21M | 379.44M | 372.19M | 75.54M | 70M | 1.48B |
| Net Debt | 90.14M | 12.55M | 87.17M | 137.2M | 78.66M | 86.96M | -85.28M | -215.61M | -1.05B | 945.61M |
| Debt / Equity | 0.23x | 0.24x | 0.27x | 0.38x | 0.37x | 0.36x | 0.31x | 0.05x | 0.04x | 0.04x |
| Debt / EBITDA | - | 61.63x | - | - | 2.36x | 5.29x | 0.76x | 0.17x | 0.25x | 7.01x |
| Net Debt / EBITDA | - | 2.77x | - | - | 0.45x | 1.21x | -0.17x | -0.48x | -3.73x | -3.73x |
| Interest Coverage | -10.93x | -7.22x | -13.49x | -10.15x | 8.82x | -1.39x | 19.30x | 20.65x | 24.74x | -32.30x |
| Total Equity | 1.2B▲ 0% | 1.17B▼ 2.6% | 1.09B▼ 7.3% | 1.07B▼ 1.7% | 1.11B▲ 4.3% | 1.04B▼ 6.2% | 1.2B▲ 15.2% | 1.46B▲ 21.8% | 1.82B▲ 24.2% | 1.75B▲ 0% |
| Equity Growth % | -0.55% | -2.62% | -7.33% | -1.7% | 4.27% | -6.19% | 15.23% | 21.81% | 24.19% | 100.74% |
| Book Value per Share | 7.84 | 7.55 | 6.91 | 6.72 | 6.91 | 6.37 | 7.09 | 8.66 | 10.78 | 10.54 |
| Total Shareholders' Equity | 1.2B | 1.17B | 1.09B | 1.07B | 1.11B | 1.04B | 1.2B | 1.46B | 1.82B | 1.75B |
| Common Stock | 1.56M | 1.58M | 1.6M | 1.62M | 1.66M | 1.69M | 1.73M | 1.77M | 1.81M | 166.46M |
| Retained Earnings | -1.04B | -1.19B | -1.38B | -1.49B | -1.54B | -1.7B | -1.34B | -976.46M | -734.79M | -801.27M |
| Treasury Stock | -89.35M | -108.97M | -118.39M | -126.09M | -142.66M | -160.86M | -189.34M | -419.25M | -450.29M | 0 |
| Accumulated OCI | -3.79M | -3.28M | -1.82M | -1.35M | -3.72M | -10.89M | -3.11M | -1.97M | -2.1M | -2.91M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALKS Cash Flow Statement
Alkermes plc (ALKS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 19.19M | 99.28M | 72.08M | 82.84M | 101.72M | 21.04M | 401.35M | 439.12M | 520.75M | 520.75M |
| Operating CF Margin % | 2.12% | 9.07% | 6.16% | 7.98% | 8.67% | 1.89% | 24.13% | 28.19% | 35.28% | - |
| Operating CF Growth % | 130.08% | 417.36% | -27.4% | 14.94% | 22.78% | -79.31% | 1807.21% | 9.41% | 18.59% | -83.2% |
| Net Income | -157.94M | -139.31M | -196.62M | -110.86M | -48.17M | -158.27M | 355.76M | 367.07M | 241.66M | 152.72M |
| Depreciation & Amortization | 98.52M | 103.66M | 80.41M | 81.85M | 78.65M | 77.86M | 74.93M | 28.53M | 27.16M | 19.74M |
| Stock-Based Compensation | 83.92M | 105.36M | 100.98M | 90.16M | 87.62M | 94.25M | 100.91M | 96.64M | 0 | -22.81M |
| Deferred Taxes | 7.23M | 10.62M | -319K | 9.98M | 5.08M | -32.8M | -99.9M | 40.52M | 28.77M | -2.51M |
| Other Non-Cash Items | -7.66M | 26.37M | 22.22M | -1.43M | 4.08M | 27.28M | 6.33M | 4.51M | 104.03M | 132.53M |
| Working Capital Changes | -4.88M | -7.42M | 65.41M | 13.13M | -25.55M | 12.71M | -36.66M | -98.15M | 119.12M | 75.79M |
| Change in Receivables | -42.49M | -58.63M | 29.98M | -18.05M | -38.01M | 25.25M | -44.51M | -56.34M | 30.17M | -14.94M |
| Change in Inventory | -30.19M | -2.67M | -13.08M | -22.93M | -24.77M | -31.02M | -2.71M | 3.09M | -14.06M | -12.31M |
| Change in Payables | 72.66M | 46.74M | 34.85M | 59.04M | 43.31M | 15.53M | 23.01M | -57.97M | 100.89M | 102.57M |
| Cash from Investing | -18.36M | -22.2M | -141.83M | -11.48M | -66.2M | -64.54M | 53.36M | -111.31M | 295.5M | 286.39M |
| Capital Expenditures | -51.3M | -69.43M | -90.94M | -42.22M | -29.02M | -38.26M | -48.05M | -33.48M | -40.42M | -30.31M |
| CapEx % of Revenue | 5.68% | 6.34% | 7.77% | 4.06% | 2.47% | 3.44% | 2.89% | 2.15% | 2.74% | - |
| Acquisitions | 162K | 507K | -7.97M | 2.75M | -713K | 485K | 0 | 97.98M | 2.79M | 1.08M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 162K | 507K | 10M | 4.53M | 8.94M | 1.27M | 354K | 461K | 0 | 0 |
| Cash from Financing | 4.08M | -1.62M | 6.76M | -2.17M | 29.07M | -1.57M | -289.71M | -494.14M | 12.38M | 11.63M |
| Debt Issued (Net) | 0 | -743K | -2.84M | -2.84M | 20.32M | -3M | -3M | -291.79M | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 9.61M | 672K | 8.75M | 1.43M | -11.71M | -200.28M | 12.38M | -17.15M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -16.43M | -19.62M | -9.32M | -7.7M | -16.57M | -18.2M | -28.47M | -200.28M | -31.03M | -31.03M |
| Other Financing | 4.08M | -877K | 0 | 0 | 0 | 0 | -275M | -2.06M | 0 | 28.78M |
| Net Change in Cash | 4.92M▲ 0% | 75.47M▲ 1434.5% | -62.99M▼ 183.5% | 69.19M▲ 209.8% | 64.58M▼ 6.7% | -45.07M▼ 169.8% | 165M▲ 466.1% | -166.32M▼ 200.8% | 828.63M▲ 598.2% | -399.81M▲ 0% |
| Free Cash Flow | -32.11M▲ 0% | 29.85M▲ 193.0% | -18.86M▼ 163.2% | 40.62M▲ 315.3% | 72.69M▲ 79.0% | -17.21M▼ 123.7% | 353.31M▲ 2152.8% | 405.64M▲ 14.8% | 480.33M▲ 18.4% | 391.63M▲ 0% |
| FCF Margin % | -3.55% | 2.73% | -1.61% | 3.91% | 6.19% | -1.55% | 21.24% | 26.04% | 32.55% | 25.07% |
| FCF Growth % | 70.12% | 192.96% | -163.2% | 315.34% | 78.95% | -123.68% | 2152.79% | 14.81% | 18.41% | -18.68% |
| FCF per Share | -0.21 | 0.19 | -0.12 | 0.26 | 0.45 | -0.11 | 2.08 | 2.40 | 2.85 | 2.85 |
| FCF Conversion (FCF/Net Income) | -0.12x | -0.71x | -0.37x | -0.75x | -2.11x | -0.13x | 1.13x | 1.20x | 2.15x | 2.56x |
| Interest Paid | 11.14M | 12.53M | 0 | 8.29M | 6.9M | 13.56M | 22.75M | 23.01M | 0 | 0 |
| Taxes Paid | 2.99M | 754K | 0 | 620K | 1.89M | 20.75M | 44.24M | 2.59M | 0 | 0 |
ALKS Key Ratios
Alkermes plc (ALKS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -13.1% | -11.74% | -17.43% | -10.3% | -4.42% | -14.68% | 31.67% | 27.52% | 14.72% | 8.82% |
| Return on Invested Capital (ROIC) | -8.53% | -6% | -11.17% | -7.1% | 6.12% | -0.39% | 27.63% | 26.66% | 18.87% | 18.87% |
| Gross Margin | 82.87% | 83.88% | 84.59% | 82.83% | 83.19% | 80.39% | 84.79% | 84.25% | 86.69% | 65.42% |
| Net Margin | -17.48% | -12.73% | -16.79% | -10.67% | -4.1% | -14.24% | 21.39% | 23.57% | 16.37% | 9.78% |
| Debt / Equity | 0.23x | 0.24x | 0.27x | 0.38x | 0.37x | 0.36x | 0.31x | 0.05x | 0.04x | 0.04x |
| Interest Coverage | -10.93x | -7.22x | -13.49x | -10.15x | 8.82x | -1.39x | 19.30x | 20.65x | 24.74x | -32.30x |
| FCF Conversion | -0.12x | -0.71x | -0.37x | -0.75x | -2.11x | -0.13x | 1.13x | 1.20x | 2.15x | 2.56x |
| Revenue Growth | 21.15% | 21.13% | 7.01% | -11.29% | 13% | -5.28% | 49.61% | -6.36% | -5.25% | 3.21% |
ALKS SEC Filings & Documents
Alkermes plc (ALKS) SEC filings — annual & quarterly reports (10-K, 10-Q)
ALKS Frequently Asked Questions
Alkermes plc (ALKS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Alkermes plc (ALKS) reported $1.56B in revenue for fiscal year 2025. This represents a 7780% increase from $19.8M in 1996.
Alkermes plc (ALKS) saw revenue decline by 5.2% over the past year.
Yes, Alkermes plc (ALKS) is profitable, generating $152.7M in net income for fiscal year 2025 (16.4% net margin).
Dividend & Returns
Alkermes plc (ALKS) has a return on equity (ROE) of 14.7%. This is reasonable for most industries.
Alkermes plc (ALKS) generated $391.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More ALKS
Alkermes plc (ALKS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates